

Jeeyun Lee

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2172793/jeeyun-lee-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

384
papers

11,115
citations

45
h-index

97
g-index

409
ext. papers

14,418
ext. citations

5.3
avg. IF

5.9
L-index

#	Paper	IF	Citations
384	Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial.. <i>Genome Medicine</i> , 2022 , 14, 1	14.4	2
383	Safety and anti-tumor effects of vismodegib in patients with refractory advanced gastric cancer: A single-arm, phase-II trial.. <i>Journal of Cancer</i> , 2022 , 13, 1097-1102	4.5	0
382	Pembrolizumab with or without chemotherapy versus chemotherapy alone for patients with PD-L1 β positive advanced gastric or gastroesophageal junction adenocarcinoma: Update from the phase 3 KEYNOTE-062 trial.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 243-243	2.2	3
381	Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2 β positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01).. <i>Journal of Clinical Oncology</i> , 2022 , 40, 243-243	2.2	0
380	Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2+ gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 293-293	2.2	2
379	Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with Fusion-Positive Solid Tumors.. <i>Clinical Cancer Research</i> , 2022 ,	12.9	10
378	A liquid biopsy signature predicts treatment response to fluoropyrimidine plus platinum therapy in patients with metastatic or unresectable gastric cancer: implications for precision oncology.. <i>Molecular Cancer</i> , 2022 , 21, 9	42.1	0
377	Prediction of epithelial-to-mesenchymal transition molecular subtype using CT in gastric cancer. <i>European Radiology</i> , 2022 , 32, 1-11	8	1
376	Genomic sequencing for bladder urothelial carcinoma and its clinical implications for immunotherapy.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 551-551	2.2	
375	Incidence of FGFR2 Amplification and FGFR2 Fusion in Patients with Metastatic Cancer Using Clinical Sequencing.. <i>Journal of Oncology</i> , 2022 , 2022, 9714570	4.5	0
374	Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor-Amplified Gastroesophageal Cancer: Retrospective Global Experience.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102453	2.2	2
373	Determining Which Patients Require Preoperative Pelvic Radiotherapy Before Curative-Intent Surgery and/or Ablation for Metastatic Rectal Cancer.. <i>Annals of Surgical Oncology</i> , 2022 , 1	3.1	1
372	Expression of SLC22A18 regulates oxaliplatin resistance by modulating the ERK pathway in colorectal cancer.. <i>American Journal of Cancer Research</i> , 2022 , 12, 1393-1408	4.4	
371	Tumour mutational burden predicts resistance to EGFR/BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancer.. <i>European Journal of Cancer</i> , 2021 , 161, 90-98	7.5	3
370	409 Trial in progress: a phase 2 study to assess the safety, efficacy of FLX475 combined with pembrolizumab in patients with advanced or metastatic gastric cancer 2021 , 9, A440-A440		
369	The Impact of Tumor Mutation Burden on the Effect of Frontline Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Advanced Gastric Cancers.. <i>Frontiers in Oncology</i> , 2021 , 11, 792340	5.3	0
368	Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study. <i>Lancet Oncology</i> , 2021 , 22, 1740-1751	21.7	2

367	Prognostic significance of sarcopenia in microsatellite-stable gastric cancer patients treated with programmed death-1 inhibitors. <i>Gastric Cancer</i> , 2021 , 24, 457-466	7.6	9
366	EGFR Amplification in Metastatic Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 1561-1569	9.7	3
365	Clinical profile of cutaneous adverse events of immune checkpoint inhibitors in a single tertiary center. <i>Journal of Dermatology</i> , 2021 , 48, 979-988	1.6	0
364	Determinants of Response and Intrinsic Resistance to PD-1 Blockade in Microsatellite Instability-High Gastric Cancer. <i>Cancer Discovery</i> , 2021 , 11, 2168-2185	24.4	27
363	Multimodal circulating tumor DNA (ctDNA) colorectal neoplasia detection assay for asymptomatic and early-stage colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3536-3536	2.2	0
362	ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma. <i>Nature</i> , 2021 , 594, 418-423	50.4	20
361	Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 4700-4709	12.9	17
360	Contextualizing a single-arm trial of ceralasertib (cer) plus paclitaxel with real-world data (RWD) in patients (pts) with advanced melanoma previously treated with anti-PD-(L)1(PDx) therapies.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e21542-e21542	2.2	
359	Phase II study of ceralasertib (AZD6738), in combination with durvalumab in patients with metastatic melanoma who have failed prior anti-PD-1 therapy.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9514-9514	2.2	2
358	Machine-learning model derived gene signature predictive of paclitaxel survival benefit in gastric cancer: results from the randomised phase III SAMIT trial. <i>Gut</i> , 2021 ,	19.2	6
357	Validation of the Combined Biomarker for Prediction of Response to Checkpoint Inhibitor in Patients with Advanced Cancer. <i>Cancers</i> , 2021 , 13,	6.6	1
356	Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials. <i>JAMA Oncology</i> , 2021 , 7, 895-902	13.4	43
355	The Right Treatment of the Right Patient: Integrating Genetic Profiling Into Clinical Decision Making in Advanced Gastric Cancer in Asia. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021 , 41, 1-8	7.1	4
354	A phase I study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors. <i>Investigational New Drugs</i> , 2021 , 39, 1624-1632	4.3	
353	Prognostic Impact of Sarcopenia and Radiotherapy in Patients With Advanced Gastric Cancer Treated With Anti-PD-1 Antibody. <i>Frontiers in Immunology</i> , 2021 , 12, 701668	8.4	2
352	Incorporating sarcopenia and inflammation with radiation therapy in patients with hepatocellular carcinoma treated with nivolumab. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 70, 1593-1603	7.4	9
351	Programmed Death Ligand 1 Expression as a Prognostic Marker in Patients with Advanced Biliary Tract Cancer. <i>Oncology</i> , 2021 , 99, 365-372	3.6	2
350	Prognostic Factors of Survival with Aflibercept and FOLFIRI (fluorouracil, leucovorin, irinotecan) as Second-line Therapy for Patients with Metastatic Colorectal Cancer. <i>Journal of Cancer</i> , 2021 , 12, 460-466 ^{4.5}		2

349	When to apply immune checkpoint inhibitor in patients with refractory advanced gastric cancer. <i>Journal of Cancer</i> , 2021 , 12, 5681-5686	4.5	
348	Chromatin accessibility of circulating CD8 T cells predicts treatment response to PD-1 blockade in patients with gastric cancer. <i>Nature Communications</i> , 2021 , 12, 975	17.4	8
347	Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition. <i>Gut</i> , 2021 ,	19.2	3
346	Microsatellite Instability and Effectiveness of Adjuvant Treatment in pT1N1 Gastric Cancer: A Multicohort Study. <i>Annals of Surgical Oncology</i> , 2021 , 28, 8908-8915	3.1	1
345	The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021 , 1	4.9	
344	ASO Video Abstract: Microsatellite Instability and the Effectiveness of Adjuvant Treatment in pT1N1 Gastric Cancer-A Multi-cohort Study. <i>Annals of Surgical Oncology</i> , 2021 , 28, 688	3.1	
343	Reducing tumor invasiveness by ramucirumab and TGF- β receptor kinase inhibitor in a diffuse-type gastric cancer patient-derived cell model. <i>Cancer Medicine</i> , 2021 , 10, 7253-7262	4.8	1
342	Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors. <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 1758835921992992	5.4	11
341	Comprehensive molecular characterization of gastric cancer patients from phase II second-line ramucirumab plus paclitaxel therapy trial. <i>Genome Medicine</i> , 2021 , 13, 11	14.4	9
340	Comprehensive molecular profiling to predict clinical outcomes in pancreatic cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 17588359211038478	5.4	0
339	Analysis of inpatient heterogeneity of circulating tumor cells at the single-cell level in the cerebrospinal fluid of a patient with metastatic gastric cancer. <i>Journal of Cancer Research and Therapeutics</i> , 2021 , 17, 1047-1051	1.2	0
338	Zanidatamab (ZW25) in HER2-expressing gastroesophageal adenocarcinoma (GEA): Results from a phase I study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 164-164	2.2	11
337	Early Tumor-Immune Microenvironmental Remodeling and Response to Frontline Fluoropyrimidine and Platinum Chemotherapy in Advanced Gastric Cancer.. <i>Cancer Discovery</i> , 2021 ,	24.4	4
336	Clinical and molecular distinctions in patients with refractory colon cancer who benefit from regorafenib treatment. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920965842	5.4	3
335	Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine (a CYP1A2 Substrate) in Patients With BRAF Mutation-Positive Malignancies. <i>Clinical Pharmacology in Drug Development</i> , 2020 , 9, 651-658	2.3	1
334	Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer.. <i>Translational Cancer Research</i> , 2020 , 9, 3367-3374	0.3	4
333	Efficacy of intravenous iron treatment for chemotherapy-induced anemia: A prospective Phase II pilot clinical trial in South Korea. <i>PLoS Medicine</i> , 2020 , 17, e1003091	11.6	5
332	A Pilot Study of Baseline Spatial Genomic Heterogeneity in Primary Gastric Cancers Using Multi-Region Endoscopic Sampling. <i>Frontiers in Oncology</i> , 2020 , 10, 225	5.3	4

331	Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2418-2426	2.2	33
330	Antitumor activity and safety of sirolimus for solid tumors with PIK3CA mutations: A multicenter, open-label, prospective single-arm study (KM 02-01, KCSG UN17-16).. <i>Translational Cancer Research</i> , 2020 , 9, 3222-3230	0.3	0
329	TPK1 as a predictive marker for the anti-tumour effects of simvastatin in gastric cancer. <i>Pathology Research and Practice</i> , 2020 , 216, 152820	3.4	2
328	Detection of Fusion Genes Using a Targeted RNA Sequencing Panel in Gastrointestinal and Rare Cancers. <i>Journal of Oncology</i> , 2020 , 2020, 4659062	4.5	2
327	High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features. <i>Pathology Research and Practice</i> , 2020 , 216, 152881	3.4	22
326	High-level FGFR2 amplification is associated with poor prognosis and Lower response to chemotherapy in gastric cancers. <i>Pathology Research and Practice</i> , 2020 , 216, 152878	3.4	11
325	Comprehensive pharmacogenomic characterization of gastric cancer. <i>Genome Medicine</i> , 2020 , 12, 17	14.4	8
324	Use of Gefitinib in EGFR-Amplified Refractory Solid Tumors: An Open-Label, Single-Arm, Single-Center Prospective Pilot Study. <i>Targeted Oncology</i> , 2020 , 15, 185-192	5	1
323	99mTc-MIBI uptake as a marker of mitochondrial membrane potential in cancer cells and effects of MDR1 and verapamil. <i>PLoS ONE</i> , 2020 , 15, e0228848	3.7	3
322	Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors. <i>BMC Ophthalmology</i> , 2020 , 20, 19	2.3	16
321	Association Between Spatial Heterogeneity Within Nonmetastatic Gastroesophageal Adenocarcinomas and Survival. <i>JAMA Network Open</i> , 2020 , 3, e203652	10.4	12
320	CDH1 mutations in gastric cancers are not associated with family history. <i>Pathology Research and Practice</i> , 2020 , 216, 152941	3.4	2
319	Clinical scoring system for the prediction of survival of patients with advanced gastric cancer. <i>ESMO Open</i> , 2020 , 5,	6	10
318	Outcomes of Radiotherapy for Mesenchymal and Non-Mesenchymal Subtypes of Gastric Cancer. <i>Cancers</i> , 2020 , 12,	6.6	2
317	Synergistic Effects of Combination Therapy with AKT and mTOR Inhibitors on Bladder Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	6
316	Tumor Mutational Burden Determined by Panel Sequencing Predicts Survival After Immunotherapy in Patients With Advanced Gastric Cancer. <i>Frontiers in Oncology</i> , 2020 , 10, 314	5.3	31
315	Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma. <i>Clinical Cancer Research</i> , 2020 , 26, 846-854	12.9	43
314	401 Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors 2020 , 8, A426-A426		2

313	A phase I study of TGF- β inhibitor, vactosertib in combination with imatinib in patients with advanced desmoid tumor (aggressive fibromatosis).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 11557-11557 ^{2,2}	2.2	2
312	A phase I study of ALX148, a CD47 blocker, in combination with standard anticancer antibodies and chemotherapy regimens in patients with advanced malignancy.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3056-3056	2.2	7
311	Results from a phase I, open-label study of ceralasertib (AZD6738), a novel DNA damage repair agent, in combination with weekly paclitaxel in refractory cancer (NCT02630199).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3503-3503	2.2	7
310	Efficacy and safety of entrectinib in patients (pts) with NTRK-fusion positive (NTRK-fp) solid tumors: An updated integrated analysis.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3605-3605	2.2	22
309	Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized, phase II, multicenter, open-label study (DESTINY-Gastric01).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4513-4513	2.2	4
308	Pembrolizumab (pembro) versus standard of care chemotherapy (chemo) in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4523-4523	2.2	5
307	Safety and preliminary clinical activity of the MET antibody mixture, Sym015 in advanced non-small cell lung cancer (NSCLC) patients with MET amplification/exon 14 deletion (METAmpl/Ex14 Δ).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 9510-9510	2.2	11
306	Pembrolizumab (pembro) in microsatellite instability-high (MSI-H) advanced gastric/gastroesophageal junction (G/GEJ) cancer by line of therapy.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 430-430	2.2	8
305	Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo) + BL-8040 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 712-712	2.2	0
304	A clinical scoring system for survival prediction in advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 436-436	2.2	
303	Pemetrexed plus erlotinib as a salvage treatment in high EGFR-expressing metastatic colorectal cancer patients following failure of standard chemotherapy: A phase II single-arm prospective study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 104-104	2.2	
302	Impact of Radiotherapy on Kidney Function among Patients Who Received Adjuvant Treatment for Gastric Cancer: Logistic and Linear Regression Analyses. <i>Cancers</i> , 2020 , 13,	6.6	4
301	A Multi-cohort Study of the Prognostic Significance of Microsatellite Instability or Mismatch Repair Status after Recurrence of Resectable Gastric Cancer. <i>Cancer Research and Treatment</i> , 2020 , 52, 1153-1161	5.2	5
300	Molecular features for selecting Asian metastatic melanoma patients who benefit from check-point inhibitors.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e22011-e22011	2.2	
299	Novel target discovery in pembrolizumab-resistant gastric cancer using a comprehensive RNA-seq analysis pipeline.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e16541-e16541	2.2	
298	Initial safety run-in findings with bavituximab plus pembrolizumab in patients with advanced gastric or gastroesophageal cancer.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e16537-e16537	2.2	
297	Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo) + PEGPH20 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4540-4540	2.2	0
296	Correlation between RICTOR overexpression and amplification in advanced solid tumors. <i>Pathology Research and Practice</i> , 2020 , 216, 152734	3.4	2

295	Development of tuberculosis in cancer patients receiving immune checkpoint inhibitors. <i>Respiratory Medicine</i> , 2020 , 161, 105853	4.6	13
294	Pemetrexed/Erlotinib as a Salvage Treatment in Patients with High EGFR-Expressing Metastatic Colorectal Cancer Following Failure of Standard Chemotherapy: A Phase II Single-Arm Prospective Study. <i>Targeted Oncology</i> , 2020 , 15, 67-73	5	1
293	Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions. <i>Genome Medicine</i> , 2020 , 12, 80	14.4	39
292	Delivering Cancer Care During the COVID-19 Pandemic: Recommendations and Lessons Learned From ASCO Global Webinars. <i>JCO Global Oncology</i> , 2020 , 6, 1461-1471	3.7	26
291	Tumor-promoting macrophages prevail in malignant ascites of advanced gastric cancer. <i>Experimental and Molecular Medicine</i> , 2020 , 52, 1976-1988	12.8	6
290	Effect of baseline sarcopenia on adjuvant treatment for D2 dissected gastric cancer: Analysis of the ARTIST phase III trial. <i>Radiotherapy and Oncology</i> , 2020 , 152, 19-25	5.3	2
289	First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920926796	5.4	5
288	Phase I clinical trial of KML001 monotherapy in patients with advanced solid tumors. <i>Expert Opinion on Investigational Drugs</i> , 2020 , 29, 1059-1067	5.9	1
287	IL-7R α CD8 T Cells from Healthy Individuals Are Anergic with Defective Glycolysis. <i>Journal of Immunology</i> , 2020 , 205, 2968-2978	5.3	1
286	Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2020 , 6, 1571-1580	13.4	196
285	Prognostic value of mismatch repair deficiency in patients with advanced gastric cancer, treated by surgery and adjuvant 5-fluorouracil and leucovorin chemoradiotherapy. <i>European Journal of Surgical Oncology</i> , 2020 , 46, 189-194	3.6	5
284	A Randomized Controlled Trial of Epidermal Growth Factor Ointment for Treating Epidermal Growth Factor Receptor Inhibitor-Induced Skin Toxicities. <i>Oncologist</i> , 2020 , 25, e186-e193	5.7	5
283	PD-L1 expression in gastric cancer determined by digital image analyses: pitfalls and correlation with pathologist interpretation. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020 , 476, 243-250	5.1	7
282	Mechanisms of Acquired Resistance to Savolitinib, a Selective MET Inhibitor in -Amplified Gastric Cancer. <i>JCO Precision Oncology</i> , 2020 , 4,	3.6	7
281	Impact of Prior Ramucirumab Use on Treatment Outcomes of Checkpoint Inhibitors in Advanced Gastric Cancer Patients. <i>Targeted Oncology</i> , 2020 , 15, 203-209	5	
280	Association of serine/threonine kinase 11 mutations and response to programmed cell death 1 inhibitors in metastatic gastric cancer. <i>Pathology Research and Practice</i> , 2020 , 216, 152947	3.4	6
279	Clinical significance of radiotherapy before and/or during nivolumab treatment in hepatocellular carcinoma. <i>Cancer Medicine</i> , 2019 , 8, 6986-6994	4.8	17
278	Anti-leukemic effects of simvastatin on NRAS mutant acute myeloid leukemia cells. <i>Molecular Biology Reports</i> , 2019 , 46, 5859-5866	2.8	7

277	Cancer Panel Assay for Precision Oncology Clinic: Results from a 1-Year Study. <i>Translational Oncology</i> , 2019 , 12, 1488-1495	4.9	2
276	Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab. <i>Scientific Reports</i> , 2019 , 9, 14039	4.9	57
275	Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial. <i>Translational Oncology</i> , 2019 , 12, 597-601	4.9	5
274	Tumor Heterogeneity Index to Detect Human Epidermal Growth Factor Receptor 2 Amplification by Next-Generation Sequencing: A Direct Comparison Study with Immunohistochemistry. <i>Journal of Molecular Diagnostics</i> , 2019 , 21, 612-622	5.1	4
273	CCNE1 amplification is associated with liver metastasis in gastric carcinoma. <i>Pathology Research and Practice</i> , 2019 , 215, 152434	3.4	10
272	Selective colony area method for heterogeneous patient-derived tumor cell lines in anti-cancer drug screening system. <i>PLoS ONE</i> , 2019 , 14, e0215080	3.7	2
271	Prognostic Impact of Microsatellite Instability in Asian Gastric Cancer Patients Enrolled in the ARTIST Trial. <i>Oncology</i> , 2019 , 97, 38-43	3.6	14
270	Detection of (HER2) Gene Amplification Events in Cell-Free DNA and Response to Anti-HER2 Agents in a Large Asian Cancer Patient Cohort. <i>Frontiers in Oncology</i> , 2019 , 9, 212	5.3	15
269	Intratumor heterogeneity inferred from targeted deep sequencing as a prognostic indicator. <i>Scientific Reports</i> , 2019 , 9, 4542	4.9	26
268	The Impact of Primary Tumor Sidedness on the Effect of Regorafenib in Refractory Metastatic Colorectal Cancer. <i>Journal of Cancer</i> , 2019 , 10, 1611-1615	4.5	4
267	Bridging genomics and phenomics of gastric carcinoma. <i>International Journal of Cancer</i> , 2019 , 145, 2407-2417	4.1	25
266	Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial 2019 , 7, 30		43
265	Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in rectal cancer patients following neoadjuvant chemoradiotherapy. <i>Tumori</i> , 2019 , 105, 434-440	1.7	20
264	Comprehensive molecular and clinical characterization of Asian melanoma patients treated with anti-PD-1 antibody. <i>BMC Cancer</i> , 2019 , 19, 805	4.8	4
263	Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel. <i>Clinical Cancer Research</i> , 2019 , 25, 7035-7045	12.9	72
262	High delta-like ligand 4 expression correlates with a poor clinical outcome in gastric cancer. <i>Journal of Cancer</i> , 2019 , 10, 3172-3178	4.5	1
261	The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma. <i>Journal of Cancer</i> , 2019 , 10, 3140-3144	4.5	3
260	Reproduction of molecular subtypes of gastric adenocarcinoma by transcriptome sequencing of archival tissue. <i>Scientific Reports</i> , 2019 , 9, 9675	4.9	6

259	Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial. <i>Cancer Discovery</i> , 2019 , 9, 1388-1405	24.4	78
258	-Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape. <i>Oncologist</i> , 2019 , 24, 1462-1468	5.7	6
257	Clinical Outcomes and the Role of Adjuvant Concurrent Chemoradiation Therapy in D2-resected LN-positive Young Patients (45 Years) With Gastric Cancer. <i>Anticancer Research</i> , 2019 , 39, 5811-5820	2.3	4
256	Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients. <i>Scientific Reports</i> , 2019 , 9, 15365	4.9	34
255	A phase I study of ALX148, a CD47 blocker, in combination with established anticancer antibodies in patients with advanced malignancy.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2514-2514	2.2	13
254	Belvarafenib, a novel pan-RAF inhibitor, in solid tumor patients harboring BRAF, KRAS, or NRAS mutations: Phase I study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3000-3000	2.2	13
253	First-in-human phase I trial of anti-hepatocyte growth factor (HGF) antibody (YYB101) in refractory solid tumor patients: Integrative pathologic-genomic analysis and the final results.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3104-3104	2.2	1
252	ARTIST 2: Interim results of a phase III trial involving adjuvant chemotherapy and/or chemoradiotherapy after D2-gastrectomy in stage II/III gastric cancer (GC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4001-4001	2.2	42
251	Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1 fusion-positive non-small cell lung cancer (TRIDENT-1 study).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9011-9011	2.3	42
250	Epigenetic alternate promoter utilization and association with PD-L1 expression in EpsteinBarr virus positive gastric cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e15509-e15509	2.2	1
249	MSI-GC-01: Individual patient data (IPD) meta-analysis of microsatellite instability (MSI) and gastric cancer (GC) from four randomized clinical trials (RCTs).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 66-66	2.2	15
248	Neutralizing antibody to FGFR2 can act as a selective biomarker and potential therapeutic agent for gastric cancer with FGFR2 amplification. <i>American Journal of Translational Research (discontinued)</i> , 2019 , 11, 4508-4515	3	2
247	Landscape of Actionable Genetic Alterations Profiled from 1,071 Tumor Samples in Korean Cancer Patients. <i>Cancer Research and Treatment</i> , 2019 , 51, 211-222	5.2	5
246	A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients. <i>Cancer Research and Treatment</i> , 2019 , 51, 1128-1134	5.7	7
245	Comparison of the 7th and the 8th AJCC Staging System for Non-metastatic D2-Resected Lymph Node-Positive Gastric Cancer Treated with Different Adjuvant Protocols. <i>Cancer Research and Treatment</i> , 2019 , 51, 876-885	5.2	5
244	FGFR2-altered gastroesophageal adenocarcinomas (GEA) are a rare clinicopathologic entity with a distinct genomic landscape.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 72-72	2.2	
243	The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 213-213	2.2	
242	Comprehensive molecular characterization of clinical response in ramucirumab-treated gastric cancer patients: Phase II trial with integrated genomic profiling.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4064-4064	2.2	

241	Comprehensive genomic profiling of circulating cell-free DNA (cfDNA) distinguishes focal amplification (amp) from aneuploidy among MET amps in diverse advanced cancer types.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3046-3046	2.2	
240	Phase 1a study results investigating the safety and preliminary efficacy of ABL001 (NOV1501), a bispecific antibody targeting VEGF and DLL4 in metastatic gastrointestinal (GI) cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3023-3023	2.2	1
239	Detection of circulating tumor cells (CTCs) in cerebrospinal fluid of a patient with HER2-overexpressing gastric cancer and single cell analysis of intra-patient heterogeneity of CTCs.. <i>Translational Cancer Research</i> , 2019 , 8, 2107-2112	0.3	
238	Acral malignant melanoma; emphasis on the primary metastasis and the usefulness of preoperative ultrasound for sentinel lymph node metastasis. <i>Scientific Reports</i> , 2019 , 9, 15894	4.9	1
237	Systematic Evaluation of Gastric Tumor Cell Index and Two-Drug Combination Therapy via 3-Dimensional High-Throughput Drug Screening. <i>Frontiers in Oncology</i> , 2019 , 9, 1327	5.3	5
236	Capecitabine plus Oxaliplatin as a Second-Line Therapy for Advanced Biliary Tract Cancers: A Multicenter, Open-Label, Phase II Trial. <i>Journal of Cancer</i> , 2019 , 10, 6185-6190	4.5	3
235	RRAD expression in gastric and colorectal cancer with peritoneal carcinomatosis. <i>Scientific Reports</i> , 2019 , 9, 19439	4.9	3
234	Atypical Mutations in Metastatic Colorectal Cancer.. <i>JCO Precision Oncology</i> , 2019 , 3, 1-11	3.6	
233	MET is overexpressed in microsatellite instability-high gastric carcinoma. <i>Pathology Research and Practice</i> , 2019 , 215, 433-438	3.4	3
232	Genomic landscape of synchronous tubulovillous adenoma and multiple non-familial colon cancers from a single patient. <i>Cancer Genetics</i> , 2019 , 231-232, 54-61	2.3	1
231	Safety and efficacy of trastuzumab administered as a 30-min infusion in patients with HER2-positive advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2019 , 83, 501-508	3.5	5
230	The use of regorafenib for patients with refractory metastatic colorectal cancer in clinical practice. <i>OncoTargets and Therapy</i> , 2019 , 12, 225-231	4.4	4
229	MCT4 Expression Is a Potential Therapeutic Target in Colorectal Cancer with Peritoneal Carcinomatosis. <i>Molecular Cancer Therapeutics</i> , 2018 , 17, 838-848	6.1	26
228	Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Digoxin in Patients With BRAF Mutation-Positive Metastatic Malignancy. <i>Journal of Clinical Pharmacology</i> , 2018 , 58, 1067-1073	2.9	9
227	Four distinct immune microenvironment subtypes in gastric adenocarcinoma with special reference to microsatellite instability. <i>ESMO Open</i> , 2018 , 3, e000326	6	40
226	Phase I Trial of Anti-MET Monoclonal Antibody in MET-Overexpressed Refractory Cancer. <i>Clinical Colorectal Cancer</i> , 2018 , 17, 140-146	3.8	11
225	Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype. <i>Nature Communications</i> , 2018 , 9, 1777	17.4	116
224	c-MET Overexpression in Colorectal Cancer: A Poor Prognostic Factor for Survival. <i>Clinical Colorectal Cancer</i> , 2018 , 17, 165-169	3.8	44

223	Adjuvant Chemotherapy Versus Chemoradiotherapy Versus Surgery Alone for Early Gastric Cancer with One or Two Lymph Node Metastasis. <i>Annals of Surgical Oncology</i> , 2018 , 25, 1616-1624	3.1	12
222	The Correlation Between Serum Chemokines and Clinical Outcome in Patients with Advanced Biliary Tract Cancer. <i>Translational Oncology</i> , 2018 , 11, 353-357	4.9	6
221	Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. <i>Cancer Discovery</i> , 2018 , 8, 37-48	24.4	162
220	The impact of microsatellite instability status and sidedness of the primary tumor on the effect of bevacizumab-containing chemotherapy in patients with metastatic colorectal cancer. <i>Journal of Cancer</i> , 2018 , 9, 1791-1796	4.5	5
219	Necessity of adjuvant concurrent chemo-radiotherapy in D2-resected LN-positive gastric cancer. <i>Radiotherapy and Oncology</i> , 2018 , 129, 306-312	5.3	11
218	Pazopanib monotherapy in the treatment of pretreated, metastatic uterine sarcoma: a single-center retrospective study. <i>Journal of Gynecologic Oncology</i> , 2018 , 29, e3	4	10
217	Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. <i>Nature Medicine</i> , 2018 , 24, 1449-1458	50.5	577
216	Primary malignant melanoma of the uterine cervix treated with pembrolizumab after radical surgery: a case report and literature review. <i>Obstetrics and Gynecology Science</i> , 2018 , 61, 524-528	1.9	7
215	Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations. <i>Cancer Discovery</i> , 2018 , 8, 1227-1236	24.4	194
214	Estimating Survival Probabilities of Advanced Gastric Cancer Patients in the Second-Line Setting: The Gastric Life Nomogram. <i>Oncology</i> , 2018 , 95, 344-352	3.6	9
213	Pemetrexed Monotherapy as Salvage Treatment in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy: A Phase II Single-arm Prospective Trial. <i>Journal of Cancer</i> , 2018 , 9, 2910-2915	4.5	5
212	TP53-dependence on the effect of doxorubicin and Src inhibitor combination therapy. <i>Tumor Biology</i> , 2018 , 40, 1010428318794217	2.9	3
211	A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors. <i>Nature Genetics</i> , 2018 , 50, 979-989	36.3	90
210	Transcriptional analysis of immune genes in Epstein-Barr virus-associated gastric cancer and association with clinical outcomes. <i>Gastric Cancer</i> , 2018 , 21, 1064-1070	7.6	18
209	A phase 1 study of the next-generation ALK/ROS1/TRK inhibitor ropotrectinib (TPX-0005) in patients with advanced ALK/ROS1/NTRK+ cancers (TRIDENT-1).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2513-2513	2.2	11
208	Safety and efficacy of durvalumab in combination with tremelimumab, durvalumab monotherapy, and tremelimumab monotherapy in patients with advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 4031-4031	2.2	9
207	Selumetinib plus docetaxel as second-line chemotherapy in KRAS mutant, KRAS amplified or MEK signatred gastric cancer patients: First arm of the umbrella trial in GC though the molecular screening, VIKTORY trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 4061-4061	2.2	1
206	First-in-human phase I trial of anti-hepatocyte growth factor (HGF) antibody (YYB101) in refractory solid tumor patients.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e14501-e14501	2.2	1

205	Results from the safety interim analysis of the Adjuvant chemoRadioTherapy In Stomach Tumors 2 (ARTIST 2) randomized, multi-center clinical trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e16029-e16029	2.2	1
204	Prediction of clinical outcomes for early gastric cancer using radiomic signatures derived from the quantitative texture analysis of conventional CT scans and machine learning.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e16091-e16091	2.2	1
203	Gemcitabine and Docetaxel Combination for Advanced Soft Tissue Sarcoma: A Nationwide Retrospective Study. <i>Cancer Research and Treatment</i> , 2018 , 50, 175-182	5.2	8
202	Pilot trial of epidermal growth factor (EGF) ointment for the patients with epidermal growth factor receptor (EGFR) inhibitor related skin side effects.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 10054-10054	2.2	
201	VariantPlex panel to detect genomic aberrations in oncology patients with rare cancer type.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e24234-e24234	2.2	
200	Co-existing alterations in cell-cycle pathway genes and impact on benefit from trastuzumab in advanced esophagogastric cancers (EGC): Analysis of 527 Her2-amplified cases.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 4063-4063	2.2	
199	Detection of targetable fusions using FusionPlex in oncology patients.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e24238-e24238	2.2	
198	Transcriptional analysis of immune genes in Epstein-Barr virus-associated gastric cancer and association with clinical outcomes.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e16024-e16024	2.2	
197	Molecular Characterization of Urothelial Carcinoma of the Bladder and Upper Urinary Tract. <i>Translational Oncology</i> , 2018 , 11, 37-42	4.9	22
196	Deep Learning-Based Survival Analysis Identified Associations Between Molecular Subtype and Optimal Adjuvant Treatment of Patients With Gastric Cancer. <i>JCO Clinical Cancer Informatics</i> , 2018 , 2, 1-14	5.2	11
195	Low ATM expression and progression-free and overall survival in advanced gastric cancer patients treated with first-line XELOX chemotherapy. <i>Journal of Gastrointestinal Oncology</i> , 2018 , 9, 1198-1206	2.8	3
194	Triptolide as a novel agent in pancreatic cancer: the validation using patient derived pancreatic tumor cell line. <i>BMC Cancer</i> , 2018 , 18, 1103	4.8	15
193	Adjuvant Chemotherapy with or without Concurrent Radiotherapy for Patients with Stage IB Gastric Cancer: a Subgroup Analysis of the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Phase III Trial. <i>Journal of Gastric Cancer</i> , 2018 , 18, 348-355	3.2	8
192	Antitumor activity of sorafenib plus CDK4/6 inhibitor in pancreatic patient derived cell with KRAS mutation. <i>Journal of Cancer</i> , 2018 , 9, 3394-3399	4.5	4
191	Protective Effects of Female Reproductive Factors on Lauren Intestinal-Type Gastric Adenocarcinoma. <i>Yonsei Medical Journal</i> , 2018 , 59, 28-34	3	12
190	Computational measurement of tumor immune microenvironment in gastric adenocarcinomas. <i>Scientific Reports</i> , 2018 , 8, 13887	4.9	9
189	NCOA4-RET fusion in colorectal cancer: Therapeutic challenge using patient-derived tumor cell lines. <i>Journal of Cancer</i> , 2018 , 9, 3032-3037	4.5	10
188	A multi-center, open-label, randomized phase III trial of first-line chemotherapy with capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer. <i>Journal of Geriatric Oncology</i> , 2017 , 8, 170-175	3.6	26

187	Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). <i>Cancer Discovery</i> , 2017 , 7, 400-409	24.4	475
186	Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors. <i>Investigational New Drugs</i> , 2017 , 35, 782-790	4.3	17
185	Antitumor Effect of AZD4547 in a Fibroblast Growth Factor Receptor 2-Amplified Gastric Cancer Patient-Derived Cell Model. <i>Translational Oncology</i> , 2017 , 10, 469-475	4.9	21
184	Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy. <i>BMC Cancer</i> , 2017 , 17, 211	4.8	21
183	Gastric adenocarcinoma. <i>Nature Reviews Disease Primers</i> , 2017 , 3, 17036	51.1	251
182	ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	126
181	Integrated genomic analyses reveal frequent aberrations in acral melanoma. <i>Genome Research</i> , 2017 , 27, 524-532	9.7	78
180	Development of Novel Patient-Derived Preclinical Models from Malignant Effusions in Patients with Tyrosine Kinase Inhibitor-Resistant Clear Cell Renal Cell Carcinoma. <i>Translational Oncology</i> , 2017 , 10, 304-310	4.9	2
179	Epigenomic Promoter Alterations Amplify Gene Isoform and Immunogenic Diversity in Gastric Adenocarcinoma. <i>Cancer Discovery</i> , 2017 , 7, 630-651	24.4	34
178	An investigation of the role of gene copy number variations in sorafenib sensitivity in metastatic hepatocellular carcinoma patients. <i>Journal of Cancer</i> , 2017 , 8, 730-736	4.5	1
177	The Clinical Impact of c-MET Over-Expression in Advanced Biliary Tract Cancer (BTC). <i>Journal of Cancer</i> , 2017 , 8, 1395-1399	4.5	17
176	The Impact of Microsatellite Instability Status and Sidedness of the Primary Tumor on the Effect of Cetuximab-Containing Chemotherapy in Patients with Metastatic Colorectal Cancer. <i>Journal of Cancer</i> , 2017 , 8, 2809-2815	4.5	10
175	The Impact of Cetuximab Plus AKT- or mTOR- Inhibitor in a Patient-Derived Colon Cancer Cell Model with Wild-Type RAS and PIK3CA Mutation. <i>Journal of Cancer</i> , 2017 , 8, 2713-2719	4.5	11
174	Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion. <i>Oncotarget</i> , 2017 , 8, 15014-15022	3.3	32
173	Prospective Feasibility Study for Using Cell-Free Circulating Tumor DNA-Guided Therapy in Refractory Metastatic Solid Cancers: An Interim Analysis. <i>JCO Precision Oncology</i> , 2017 , 1,	3.6	18
172	Direct analysis of aberrant glycosylation on haptoglobin in patients with gastric cancer. <i>Oncotarget</i> , 2017 , 8, 11094-11104	3.3	15
171	Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy. <i>Oncotarget</i> , 2017 , 8, 77415-77423	3.3	55
170	Host immune response index in gastric cancer identified by comprehensive analyses of tumor immunity. <i>Oncolimmunology</i> , 2017 , 6, e1356150	7.2	27

169	Clinical Application of Targeted Deep Sequencing in Solid-Cancer Patients and Utility for Biomarker-Selected Clinical Trials. <i>Oncologist</i> , 2017 , 22, 1169-1177	5.7	10
168	Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project. <i>Clinical Cancer Research</i> , 2017 , 23, 4441-4449	12.9	213
167	Prevalence and detection of low-allele-fraction variants in clinical cancer samples. <i>Nature Communications</i> , 2017 , 8, 1377	17.4	92
166	Pilot study of sirolimus in patients with PIK3CA mutant/amplified refractory solid cancer. <i>Molecular and Clinical Oncology</i> , 2017 , 7, 27-31	1.6	13
165	TP53 alteration determines the combinational cytotoxic effect of doxorubicin and an antioxidant NAC. <i>Tumor Biology</i> , 2017 , 39, 1010428317700159	2.9	4
164	3-Dimensional micropillar drug screening identifies FGFR2-IIIC overexpression as a potential target in metastatic giant cell tumor. <i>Oncotarget</i> , 2017 , 8, 36484-36491	3.3	6
163	Updated antitumor activity and safety of FPA144, an ADCC-enhanced, FGFR2b isoform-specific monoclonal antibody, in patients with FGFR2b+ gastric cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4067-4067	2.2	8
162	Phase II XELOX + lapatinib treatment in HER2-amplified gastric cancer: Monitoring with serial cell-free DNA genomics.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e15610-e15610	2.2	1
161	Unforeseen clonal evolution of tumor cell population in recurrent and metastatic dermatofibrosarcoma protuberans. <i>PLoS ONE</i> , 2017 , 12, e0185826	3.7	8
160	The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors. <i>Oncotarget</i> , 2017 , 8, 3237-3245	3.3	13
159	Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability. <i>Oncotarget</i> , 2017 , 8, 13320-13328	3.3	50
158	Tissue recommendations for precision cancer therapy using next generation sequencing: a comprehensive single cancer center experiences. <i>Oncotarget</i> , 2017 , 8, 42478-42486	3.3	16
157	The impact of pathologic differentiation (well/poorly) and the degree of Ki-67 index in patients with metastatic WHO grade 3 GEP-NECs. <i>Oncotarget</i> , 2017 , 8, 73974-73980	3.3	3
156	Correlation between MEK signature and Ras gene alteration in advanced gastric cancer. <i>Oncotarget</i> , 2017 , 8, 107492-107499	3.3	5
155	Development of mesenchymal subtype gene signature for clinical application in gastric cancer. <i>Oncotarget</i> , 2017 , 8, 66305-66315	3.3	19
154	MerTK inhibition by RXDX-106 in MerTK activated gastric cancer cell lines. <i>Oncotarget</i> , 2017 , 8, 105727-105734	3.3	12
153	MerTK is a novel therapeutic target in gastric cancer. <i>Oncotarget</i> , 2017 , 8, 96656-96667	3.3	17
152	IKK and TBK1 expression in gastric cancer. <i>Oncotarget</i> , 2017 , 8, 16233-16242	3.3	10

151	Effect of leukocyte alteration on treatment outcomes following preoperative chemoradiotherapy in patients with rectal cancer. <i>Radiation Oncology Journal</i> , 2017 , 35, 217-226	2.5	3
150	Ipilimumab Real-World Efficacy and Safety in Korean Melanoma Patients from the Korean Named-Patient Program Cohort. <i>Cancer Research and Treatment</i> , 2017 , 49, 44-53	5.2	19
149	Clinical and molecular landscape of metastatic colorectal cancer (mCRC) harboring ALK, ROS1, or NTRK 1, 2, 3 (NTRKs) rearrangements.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 589-589	2.2	
148	Cell free circulating tumor DNA (ctDNA) landscape in patients with advanced gastroesophageal adenocarcinoma (GEC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 47-47	2.2	2
147	Programmed death (PD)-ligand 1 (L1) expression and mismatch repair (MMR) deficiency across tumor types: Candidates for checkpoint inhibitor based immunotherapy.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e14622-e14622	2.2	
146	Post resection circulating residual disease monitoring in early stage lung and colorectal cancer patients using a circulating cell-free DNA assay with ultra-high accuracy and specificity.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e23068-e23068	2.2	
145	The impact of pathologic differentiation (well/ poorly) and the degree of Ki-67 index in patients with metastatic WHO grade 3 GEP-NECs.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e15686-e15686	2.2	
144	VIKTORY trial: Report on AZD1775/paclitaxel in TP53 mutation (+) GC, selumetinib/paclitaxel in ras aberrant GC, AZD5363/paclitaxel in PIK3CA mt and biomarker negative, savolitinib/docetaxel in met (+), and vistusertib/paclitaxel in RICTOR(+) GC.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4024-4024	2.2	1
143	NanoString expression profiling identifies candidate biomarkers of RAD001 response in metastatic gastric cancer. <i>ESMO Open</i> , 2016 , 1, e000009	6	13
142	Clinical significance of mucinous rectal adenocarcinoma following preoperative chemoradiotherapy and curative surgery. <i>Tumori</i> , 2016 , 102, 114-21	1.7	8
141	A Korean single-center, real-world, retrospective study of first-line weekly paclitaxel in patients with metastatic angiosarcoma. <i>Clinical Sarcoma Research</i> , 2016 , 6, 8	2.5	7
140	Value of FGFR2 expression for advanced gastric cancer patients receiving pazopanib plus CapeOX (capecitabine and oxaliplatin). <i>Journal of Cancer Research and Clinical Oncology</i> , 2016 , 142, 1231-7	4.9	10
139	Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target. <i>Clinical Cancer Research</i> , 2016 , 22, 3831-40	12.9	82
138	Phase II trial of epidermal growth factor ointment for patients with Erlotinib-related skin effects. <i>Supportive Care in Cancer</i> , 2016 , 24, 301-309	3.9	10
137	A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2016 , 14, 76-81	3.3	8
136	Cell-free DNA sequencing-guided therapy in a prospective clinical trial: NEXT-2 trial feasibility analysis.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 11534-11534	2.2	2
135	Antitumor activity and safety of FPA144, an ADCC-enhanced, FGFR2b isoform-selective monoclonal antibody, in patients with FGFR2b+ gastric cancer and advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2502-2502	2.2	4
134	First-in-human study of HM95573, a novel oral RAF inhibitor, in patients with solid tumors.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2570-2570	2.2	4

133	Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced gastric or gastroesophageal junction cancer from JAVELIN solid tumor phase Ib trial: Analysis of safety and clinical activity.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4009-4009	2.2	29
132	Prognostic value of the metastatic lymph node (N) ratio in the adjuvant chemoradiotherapy in stomach tumors (ARTIST) phase III trial. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4038-4038	2.2	1
131	Correlation between PD-L1 expression and PD-1 immune checkpoint blockade: A retrospective analysis for advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e21007-e21007	2.2	1
130	Integrated genomic analyses identify frequent gene fusion events and VHL inactivation in gastrointestinal stromal tumors. <i>Oncotarget</i> , 2016 , 7, 6538-51	3.3	17
129	Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors. <i>Oncotarget</i> , 2016 , 7, 4024-35	3.3	30
128	Molecular characterization of colorectal cancer patients and concomitant patient-derived tumor cell establishment. <i>Oncotarget</i> , 2016 , 7, 19610-9	3.3	10
127	Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer. <i>Oncotarget</i> , 2016 , 7, 24088-96	3.3	9
126	Prospective phase II trial of regional hyperthermia and whole liver irradiation for numerous chemorefractory liver metastases from colorectal cancer. <i>Radiation Oncology Journal</i> , 2016 , 34, 34-44	2.5	9
125	The Role of Plasma Chromogranin A as Assessment of Treatment Response in Non-functioning Gastroenteropancreatic Neuroendocrine Tumors. <i>Cancer Research and Treatment</i> , 2016 , 48, 153-61	5.2	9
124	Early, molecular detection of cancer utilizing circulating cell-free DNA assay with ultra high accuracy and sensitivity.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 11540-11540	2.2	
123	Ipilimumab real-world efficacy and safety in Asian melanoma patients from the Korean Named-Patient Program cohort.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e21002-e21002	2.2	
122	Tuberous sclerosis complex 2 (TSC2) expression in hepatocellular carcinoma to predict responses to mTOR inhibitor.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e15628-e15628	2.2	
121	The clinicopathologic features and treatment of 607 hindgut neuroendocrine tumor (NET) patients at a single institution.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4091-4091	2.2	
120	The impact of cetuximab plus AKT- or mTOR- inhibitor in patient-derived colon cancer cell model with RAS wild type and PIK3CA mutation.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e15153-e15153	2.2	
119	Moving molecular subtypes to the clinic in gastric cancer. <i>Translational Cancer Research</i> , 2016 , 5, S25-S30.	3.3	1
118	Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus. <i>Oncotarget</i> , 2016 , 7, 10547-56	3.3	44
117	Genomic Profiling of Metastatic Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients in the Personalized-Medicine Era. <i>Journal of Cancer</i> , 2016 , 7, 1044-8	4.5	13
116	To Excavate Biomarkers Predictive of the Response for Capecitabine plus RAD001 through Nanostring-Based Multigene Assay in Advanced Gastric Cancer Patients. <i>Journal of Cancer</i> , 2016 , 7, 2173-2178	4.5	1

115	Prognostic Model to Predict Survival Outcome for Curatively Resected Liposarcoma: A Multi-Institutional Experience. <i>Journal of Cancer</i> , 2016 , 7, 1174-80	4.5	22
114	A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology. <i>Cancer Research and Treatment</i> , 2016 , 48, 553-60	5.2	13
113	Gastric Adenocarcinoma: An Update on Genomics, Immune System Modulations, and Targeted Therapy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016 , 35, 104-11	7.1	11
112	The Influence of Metastatic Lymph Node Ratio on the Treatment Outcomes in the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Trial: A Phase III Trial. <i>Journal of Gastric Cancer</i> , 2016 , 16, 105-10	3.2	26
111	MCT4 as a potential therapeutic target for metastatic gastric cancer with peritoneal carcinomatosis. <i>Oncotarget</i> , 2016 , 7, 43492-43503	3.3	37
110	ADAR-Mediated RNA Editing Predicts Progression and Prognosis of Gastric Cancer. <i>Gastroenterology</i> , 2016 , 151, 637-650.e10	13.3	90
109	Efficacy of BRAF Inhibitors in Asian Metastatic Melanoma Patients: Potential Implications of Genomic Sequencing in BRAF-Mutated Melanoma. <i>Translational Oncology</i> , 2016 , 9, 557-564	4.9	11
108	FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival. <i>Modern Pathology</i> , 2016 , 29, 1095-103	9.8	49
107	Genomic Alterations in Biliary Tract Cancer Using Targeted Sequencing. <i>Translational Oncology</i> , 2016 , 9, 173-8	4.9	19
106	A nCounter CNV Assay to Detect HER2 Amplification: A Correlation Study with Immunohistochemistry and In Situ Hybridization in Advanced Gastric Cancer. <i>Molecular Diagnosis and Therapy</i> , 2016 , 20, 375-83	4.5	12
105	BEZ235 (PIK3/mTOR inhibitor) Overcomes Pazopanib Resistance in Patient-Derived Refractory Soft Tissue Sarcoma Cells. <i>Translational Oncology</i> , 2016 , 9, 197-202	4.9	8
104	The impact of KRAS mutations on prognosis in surgically resected colorectal cancer patients with liver and lung metastases: a retrospective analysis. <i>BMC Cancer</i> , 2016 , 16, 120	4.8	31
103	Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer. <i>Oncologist</i> , 2016 , 21, 1306-1314	5.7	27
102	Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry. <i>Investigational New Drugs</i> , 2016 , 34, 677-684	4.3	22
101	Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3130-6	2.2	271
100	Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. <i>Nature Medicine</i> , 2015 , 21, 449-56	50.5	1031
99	Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer. <i>BMC Cancer</i> , 2015 , 15, 530	4.8	15
98	Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series. <i>BMC Cancer</i> , 2015 , 15, 154	4.8	46

97	Effects of adjuvant radiotherapy on completely resected gastric cancer: A radiation oncologist's view of the ARTIST randomized phase III trial. <i>Radiotherapy and Oncology</i> , 2015 , 117, 171-7	5.3	29
96	The impact of concomitant genomic alterations on treatment outcome for trastuzumab therapy in HER2-positive gastric cancer. <i>Scientific Reports</i> , 2015 , 5, 9289	4.9	33
95	Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring KIT Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06). <i>Oncologist</i> , 2015 , 20, 1312-9	5.7	42
94	Clinical Significance of IGFBP-3 Methylation in Patients with Early Stage Gastric Cancer. <i>Translational Oncology</i> , 2015 , 8, 288-94	4.9	7
93	Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study. <i>BMC Cancer</i> , 2015 , 15, 693	4.8	12
92	Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan. <i>BMC Cancer</i> , 2015 , 15, 747	4.8	6
91	Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients. <i>Oncotarget</i> , 2015 , 6, 40360-9	3.3	77
90	Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA. <i>PLoS ONE</i> , 2015 , 10, e0140712	3.7	442
89	Circulating tumor cells are predictive of poor response to chemotherapy in metastatic gastric cancer. <i>International Journal of Biological Markers</i> , 2015 , 30, e382-6	2.8	19
88	Gastrointestinal malignancies harbor actionable MET exon 14 deletions. <i>Oncotarget</i> , 2015 , 6, 28211-22	3.3	48
87	Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer. <i>Translational Oncology</i> , 2015 , 8, 40-6	4.9	14
86	Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas. <i>Gut</i> , 2015 , 64, 1721-31	19.2	137
85	Changes in the mean corpuscular volume after capecitabine treatment are associated with clinical response and survival in patients with advanced gastric cancer. <i>Cancer Research and Treatment</i> , 2015 , 47, 72-7	5.2	14
84	Phase I trial and pharmacokinetic study of Tanibirumab, a fully human monoclonal antibody to the vascular endothelial growth factor receptor 2 in patients with refractory solid tumors.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2522-2522	2.2	1
83	INTEGRATE: A randomized, phase II, double-blind, placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC): A study by the Australasian Gastrointestinal Trials Group (AGITG) Final overall and subgroup results.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4003-4003	2.2	8
82	The NEXT-2 (Next Generation Personalized Tx with Plasma DNA Genomics Trial-2 in Refractory Solid Tumors: cfDNA-Based Umbrella Trial, an interim analysis).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e12540-e12540	2.2	1
81	Copy Number Gains at 8q24 and 20q11-q13 in Gastric Cancer Are More Common in Intestinal-Type than Diffuse-Type. <i>PLoS ONE</i> , 2015 , 10, e0137657	3.7	13
80	Overexpression of MAPK15 in gastric cancer is associated with copy number gain and contributes to the stability of c-Jun. <i>Oncotarget</i> , 2015 , 6, 20190-203	3.3	16

79	Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening. <i>Oncotarget</i> , 2015 , 6, 24320-32	3.3	31
78	Patient-derived cell models as preclinical tools for genome-directed targeted therapy. <i>Oncotarget</i> , 2015 , 6, 25619-30	3.3	42
77	The NEXT-1 (Next generation pERsonalized tX with mULTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis. <i>Oncotarget</i> , 2015 , 6, 33358-68	3.3	21
76	PIK3CA mutation detection in metastatic biliary cancer using cell-free DNA. <i>Oncotarget</i> , 2015 , 6, 40026-35	3.3	12
75	NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line. <i>Oncotarget</i> , 2015 , 6, 39028-35	3.3	46
74	Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma. <i>World Journal of Gastroenterology</i> , 2015 , 21, 4268-74	5.6	7
73	Gastroenteropancreatic Neuroendocrine Tumors with Liver Metastases in Korea: A Clinicopathological Analysis of 72 Cases in a Single Institute. <i>Cancer Research and Treatment</i> , 2015 , 47, 738-46	5.2	10
72	Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4049-4049	2.2	2
71	Placebo-controlled, double-blinded multi-center phase III trial of XELIRI/FOLFIRI plus simvastatin in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3576-3576	2.2	
70	Comprehensive genomic profiling of metastatic gastric cancer undergoing palliative chemotherapy at Samsung Medical Center using custom targeted deep sequencing (CancerSCAN). <i>Journal of Clinical Oncology</i> , 2015 , 33, e22173-e22173	2.2	
69	Next-generation sequencing to reveal somatic mutations that confer sensitivity to everolimus.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 11010-11010	2.2	
68	Molecular profiling of patient derived cells (PDCs) from metastatic cancer patients using CancerSCAN: Highly profiled models to test the efficacy of genome-directed therapy in cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e22241-e22241	2.2	
67	A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer. <i>Investigational New Drugs</i> , 2014 , 32, 561-8	4.3	2
66	Genomic landscape and genetic heterogeneity in gastric adenocarcinoma revealed by whole-genome sequencing. <i>Nature Communications</i> , 2014 , 5, 5477	17.4	130
65	The analysis of mutations and exon deletions at TSC2 gene in angiomyolipomas associated with tuberous sclerosis complex. <i>Experimental and Molecular Pathology</i> , 2014 , 97, 440-4	4.4	5
64	Simvastatin plus capecitabine-cisplatin versus placebo plus capecitabine-cisplatin in patients with previously untreated advanced gastric cancer: a double-blind randomised phase 3 study. <i>European Journal of Cancer</i> , 2014 , 50, 2822-30	7.5	52
63	Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab. <i>Investigational New Drugs</i> , 2014 , 32, 535-41	4.3	26
62	Aberrant CDK4 amplification in refractory rhabdomyosarcoma as identified by genomic profiling. <i>Scientific Reports</i> , 2014 , 4, 3623	4.9	21

61	Anti-tumor efficacy of fulvestrant in estrogen receptor positive gastric cancer. <i>Scientific Reports</i> , 2014 , 4, 7592	4.9	21
60	Pazopanib, a novel multitargeted kinase inhibitor, shows potent in vitro antitumor activity in gastric cancer cell lines with FGFR2 amplification. <i>Molecular Cancer Therapeutics</i> , 2014 , 13, 2527-36	6.1	26
59	Successful use of pazopanib for treatment of refractory metastatic hemangiopericytoma. <i>Clinical Sarcoma Research</i> , 2014 , 4, 13	2.5	21
58	Interim safety analysis from a randomized, open-label, multicenter, phase III trial of capecitabine plus oxaliplatin (XELOX) versus capecitabine (X) as first-line chemotherapy in elderly patients with advanced gastric cancer (AGC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 158-158	2.2	1
57	Activated cMET and IGF1R-driven PI3K signaling predicts poor survival in colorectal cancers independent of KRAS mutational status. <i>PLoS ONE</i> , 2014 , 9, e103551	3.7	21
56	High-throughput sequencing and copy number variation detection using formalin fixed embedded tissue in metastatic gastric cancer. <i>PLoS ONE</i> , 2014 , 9, e111693	3.7	32
55	Pulmonary metastasectomy for colorectal cancer: how many nodules, how many times?. <i>World Journal of Gastroenterology</i> , 2014 , 20, 6133-45	5.6	41
54	Aggressive clinical course of extramammary Paget disease after radiotherapy. <i>Radiation Oncology Journal</i> , 2014 , 32, 95-8	2.5	5
53	CD133-positive tumor cell content is a predictor of early recurrence in colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2014 , 5, 447-56	2.8	21
52	The role of pazopanib in various histologic subtypes of metastatic soft tissue sarcomas.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 10586-10586	2.2	1
51	Phase III trial to compare capecitabine/cisplatin (XP) versus XP plus concurrent capecitabine-radiotherapy in gastric cancer (GC): The final report on the ARTIST trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4008-4008	2.2	
50	Evaluation of biochemical features of anemia in cancer patients.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e20698-e20698	2.2	1
49	Ultra-high-quality sequencing assay for comprehensive genetic panel analysis of tumor-derived circulating cell-free DNA in colorectal cancer patients.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 504-504	2.2	
48	Transcriptome analysis of CD133-positive stem cells and prognostic value of survivin in colorectal cancer. <i>Cancer Genomics and Proteomics</i> , 2014 , 11, 259-66	3.3	23
47	Adjuvant chemoradiation with 5-fluorouracil/leucovorin versus S-1 in gastric cancer patients following D2 lymph node dissection surgery: a feasibility study. <i>Anticancer Research</i> , 2014 , 34, 6585-91	2.3	2
46	High level of CDK4 amplification is a poor prognostic factor in well-differentiated and dedifferentiated liposarcoma. <i>Histology and Histopathology</i> , 2014 , 29, 127-38	1.4	22
45	Identification of ROS1 rearrangement in gastric adenocarcinoma. <i>Cancer</i> , 2013 , 119, 1627-35	6.4	92
44	Exome sequencing identifies early gastric carcinoma as an early stage of advanced gastric cancer. <i>PLoS ONE</i> , 2013 , 8, e82770	3.7	31

43	Phase Ib dose-escalation study of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, administered by intravenous (IV) infusions in patients with metastatic colorectal carcinoma (mCRC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3608-3608	2.2	1
42	A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 492-492	2.2	1
41	Nomogram to predict treatment outcome of fluoropyrimidine/platinum-based chemotherapy in metastatic esophageal squamous cell carcinoma. <i>Cancer Research and Treatment</i> , 2013 , 45, 285-94	5.2	10
40	A phase II trial of weekly docetaxel for second-line treatment of urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e15613-e15613	2.2	
39	Towards the goal of personalized medicine in gastric cancer--time to move beyond HER2 inhibition. Part I: Targeting receptor tyrosine kinase gene amplification. <i>Discovery Medicine</i> , 2013 , 15, 333-41	2.5	14
38	Towards the goal of personalized medicine in gastric cancer--time to move beyond HER2 inhibition. Part II: Targeting gene mutations and gene amplifications and the angiogenesis pathway. <i>Discovery Medicine</i> , 2013 , 16, 7-14	2.5	13
37	A comparative study of telomerase activity and cytologic diagnosis in malignant ascites. <i>Analytical and Quantitative Cytopathology and Histopathology</i> , 2013 , 35, 146-51		4
36	Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. <i>Lancet Oncology</i> , 2012 , 13, 181-8	21.7	340
35	Statins and the risk of gastric cancer in diabetes patients. <i>BMC Cancer</i> , 2012 , 12, 596	4.8	40
34	Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. <i>Journal of Clinical Oncology</i> , 2012 , 30, 268-73	2.2	537
33	Metastasis of neuroendocrine tumors are characterized by increased cell proliferation and reduced expression of the ATM gene. <i>PLoS ONE</i> , 2012 , 7, e34456	3.7	24
32	High-throughput mutation profiling identifies frequent somatic mutations in advanced gastric adenocarcinoma. <i>PLoS ONE</i> , 2012 , 7, e38892	3.7	66
31	Profiling of activated receptor tyrosine kinases in advanced gastric cancers identifies patients with poor prognosis.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4011-4011	2.2	
30	Profiling of circulating tumor cells isolated from 105 metastatic gastric cancer patients revealed HER2 overexpression/activation for potential use in clinical setting.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 10535-10535	2.2	1
29	A phase Ib dose escalation study of JX-594 (TK-vaccinia virus expressing GM-CSF) administered by biweekly intravenous infusion in patients with metastatic, refractory colorectal carcinoma.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e13044-e13044	2.2	
28	A prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver metastasis.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e14072-e14072	2.2	
27	Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target. <i>Oncology Reports</i> , 2011 , 25, 1517-24	3.5	99
26	Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations. <i>Journal of the National Cancer Institute</i> , 2011 , 103, 674-88	9.7	74

25	SSTR2A Protein Expression in Neuroendocrine Neoplasms of the Colorectum. <i>Korean Journal of Pathology</i> , 2011 , 45, 276		
24	Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study. <i>Cancer Chemotherapy and Pharmacology</i> , 2009 , 64, 657-63	3.5	63
23	Expression of activated signal transducer and activator of transcription 3 predicts poor clinical outcome in gastric adenocarcinoma. <i>Apmis</i> , 2009 , 117, 598-606	3.4	39
22	Autologous hematopoietic stem cell transplantation in extranodal natural killer/T cell lymphoma: a multinational, multicenter, matched controlled study. <i>Biology of Blood and Marrow Transplantation</i> , 2008 , 14, 1356-64	4.7	109
21	Impact of E2F-1 expression on clinical outcome of gastric adenocarcinoma patients with adjuvant chemoradiation therapy. <i>Clinical Cancer Research</i> , 2008 , 14, 82-8	12.9	35
20	Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas. <i>Cancer Chemotherapy and Pharmacology</i> , 2008 , 61, 47-52	3.5	26
19	A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2008 , 62, 77-84	3.5	34
18	Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. <i>Cancer</i> , 2007 , 109, 1561-9	6.4	113
17	Prospective clinical study of surgical resection followed by CHOP in localized intestinal diffuse large B cell lymphoma. <i>Leukemia Research</i> , 2007 , 31, 359-64	2.7	31
16	Effect of positive bone marrow EBV in situ hybridization in staging and survival of localized extranodal natural killer/T-cell lymphoma, nasal-type. <i>Clinical Cancer Research</i> , 2007 , 13, 3250-4	12.9	37
15	Nongastric Marginal Zone B-Cell Lymphoma: A Prognostic Model from a Retrospective Multicenter Study.. <i>Blood</i> , 2007 , 110, 1361-1361	2.2	
14	Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. <i>Journal of Clinical Oncology</i> , 2006 , 24, 612-8	2.2	457
13	Lovastatin-induced RhoA modulation and its effect on senescence in prostate cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2006 , 339, 748-54	3.4	51
12	Interferon-alpha resistance can be reversed by inhibition of IFN-alpha-induced COX-2 expression potentially via STAT1 activation in A549 cells. <i>Oncology Reports</i> , 2006 , 15, 1541-9	3.5	16
11	Curcumin inhibits interferon-alpha induced NF-kappaB and COX-2 in human A549 non-small cell lung cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2005 , 334, 313-8	3.4	50
10	Extranodal nasal type NK/T-cell lymphoma: elucidating clinical prognostic factors for risk-based stratification of therapy. <i>European Journal of Cancer</i> , 2005 , 41, 1402-8	7.5	136
9	Adjuvant chemotherapy with 5-fluorouracil and cisplatin in lymph node-positive thoracic esophageal squamous cell carcinoma. <i>Annals of Thoracic Surgery</i> , 2005 , 80, 1170-5	2.7	49
8	Influential factors for the collection of peripheral blood stem cells and engraftment in acute myeloid leukemia patients in first complete remission. <i>International Journal of Hematology</i> , 2005 , 81, 258-63	2.3	6

7	Nongastric Marginal Zone B-Cell Lymphoma: Analysis of 247 Cases - Clinical Presentation and Treatment Outcomes of Nongastric Marginal Zone B-Cell Lymphoma.. <i>Blood</i> , 2005 , 106, 1491-1491	2.2	
6	Intestinal lymphoma: exploration of the prognostic factors and the optimal treatment. <i>Leukemia and Lymphoma</i> , 2004 , 45, 339-44	1.9	39
5	Phase II study of gemcitabine combined with uracil-tegafur in metastatic pancreatic cancer. <i>Oncology</i> , 2004 , 66, 32-7	3.6	19
4	Tuberculosis in hematopoietic stem cell transplant recipients in Korea. <i>International Journal of Hematology</i> , 2004 , 79, 185-8	2.3	30
3	Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2004 , 54, 385-90	3.5	72
2	A Randomized Trial of Short-Course Preemptive Ganciclovir Compared with Conventional Ganciclovir Therapy To Prevent Cytomegalovirus Infection after Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2004 , 104, 3162-3162	2.2	1
1	Clinical Characteristics of Takayasu's Arteritis. <i>Sunhwanigi</i> , 2001 , 31, 1106		6